EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. Ratziu V, Rinella ME, Neuschwander-Tetri BA, Lawitz E, et al. J Hepatol 2022;76:506-517.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ratziu V, Rinella ME, Neuschwander-Tetri BA, Lawitz E, et al. EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. J Hepatol 2022;76:506-517.
PMID: 34740705